Sequential docetaxel followed by epirubicin-vinorelbine as first-line chemotherapy in advanced breast cancer
Vici, P.; Foggi, P.; Colucci, G.; Capomolla, E.; Brandi, M.; Giotta, F.; Gebbia, N.; Di Lauro, L.; Valerio, M.Rosaria.; Paoletti, G.; Belli, F.; Pizza, C.; Giannarelli, D.; Lopez, M.
Anticancer Research 25(2b): 1309-1314
2005
ISSN/ISBN: 0250-7005 PMID: 15865083 Document Number: 589354
Background: This phase H study evaluated the efficacy and the tolerability of a sequential regimen of docetaxel followed by epirubicin-vinorelbine combination as first-line chemotherapy in advanced breast cancer. Patients and Methods: Twenty-seven patients received docetaxel loo mg/m(2) (4 cycles) followed by 4 cycles of epirubicin go mg/m(2) (day 1) combined with vinorelbine 25 mg/m(2) (days 1 and 5), with cycles repeated every 3 weeks. G-CSF was administered during epirubicin-vinorelbine treatment. Results: There were 1 (3.7%) CR and 14 (51.9%) PR, for an overall response rate of 55.6% (95% CI, 36.9%-74.3%). Median time to response, time to progression and overall survival were 2, 9 and 25 months, respectively. The dose-limiting toxicity was neutropenia (grade 3 to 4 in 85% of the patients). There was one toxic death due to neutropenic fever. Gastrointestinal side-effects were generally mild. According to the Simon two-stage design the response rate was considered unsatisfactory and patient accrual was terminated. Conclusion: This sequential regimen appears to be moderately effective; possibly, a modulation of the treatment based on objective responses instead of a fixed number of cycles may be more appropriate in order to obtain better results.